Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

The dynamics of the CAR-T cell therapy market for multiple myeloma are anticipated to change due to extensive R&D activities, increased investment in research and development of new CAR-T cell ...

Scientists discovered that inhibiting the enzyme STK17B forces multiple myeloma cells into iron-driven death and makes ...

Kelley L. Julian, PharmD, BCOP, discusses optimizing MM care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives. Multiple myeloma is a cancer that begins in ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jonathan L.

(Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital ...

The multiple myeloma CAR-T market is growing due to the strong clinical success of BCMS-targeted therapies and rising cases of relapsed or refractory patients, reports Towards Healthcare a sister firm ...

Phase 2 Trial in Multiple Myeloma Nears Key ReadoutPreparing for Expansion into Sickle Cell Disease and Acute Myeloid ...